AUPH News and Press, Aurinia Pharmaceuticals Inc From 08/04/22

Shares of commercial-stage autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) raced higher in early action Thursday morning, rising as much as 15.7%. However, Aurinia's shares have given back most of these gains as the session has progressed. As of 10:58 a.m. E...

Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) slipped in the pre-market Thursday after reporting a mixed financial performance for 2Q 2022 despite a sales recovery in the company’s lupus nephritis drug Lupkynis. Net revenue for the quarter more than quadru...

Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.25 misses by $0.03 . Revenue of $28.2M (+326.0% Y/Y) beats by $1.16M . Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS (voclosporin) for 2022 For furth...

Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS ® (voclosporin) for 2022 Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage EMA ...

Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.22 (+40.5% Y/Y) and the consensus Revenue Estimate is $27.04M (+308.5% Y/Y). Over the last 3 months, EPS estimate...

ABMD , ABUS , ACIW , ADAP , OTCQX:ADDYY , ADT , AG , AGIO , AHH , APD , APO , APTV , ARW , ATI , AUPH , AUTL , AZEK , BABA , BALL , BALY , OTCPK:BAYZF , BCE , BCRX , BDX , BKI , CBRE , ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were sliding 6.5% lower as of 11:36 a.m. ET on Wednesday. The stock fell as much as 12.7% earlier in the day. This decline came after Canadian investment bank Bloom Burton & Co. downgraded Aurina stock from a buy recommendation to...

OBsEVA ( OBSV ) -73% on plans for restructuring after setback for uterine fibroids drug. F45 Training Holdings FXLV -57% on slashed guidance, job cuts, CEO exit. Cassava Sciences SAVA -24% on report of criminal probe linked to Alzheimer’s drug....

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (“IPR”) filed...